Scribes improve physician satisfaction, chart accuracy

Medical scribes are tasked with clinical documentation, but what impact to these individuals have on physician and patient satisfaction or charting efficiency? A study published in the Annals of Family Medicine evaluated scribes in their abilities to ease clinical workflow.

The study included family medicine physicians who were randomized to receive a scribe for one week followed by another week without one for a year. The scribe documentations were reviewed by physicians before signing. In the weeks without a scribe, physicians performed all charting duties.

Results showed scribes were able to improve rates of overall satisfaction—allowing physicians to have enough time with patients, while improving chart quality and accuracy. While scribes did not have an effect on patient satisfaction, they did increase the proportion of charts that were completed within 48 hours.

“To our knowledge, we have conducted the first randomized controlled trial of scribes,” concluded first author Risha Gidwani, DrPH, and colleagues. “We found that scribes produced significant improvements in overall physician satisfaction, satisfaction with chart quality and accuracy, and charting efficiency without detracting from patient satisfaction. Scribes appear to be a promising strategy to improve health care efficiency and reduce physician burnout.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.